Disse hændelser førte til, at 0, 5% af patienterne afbrød behandlingen med NEVANAC, hvilket var færre end antallet af patienter, som fik placebobehandling (1, 3%) i samme forsøg.
These events led to discontinuation in 0.5% of patients, which was less than placebo-treated patients (1.3%) in these same studies.